Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 20/20 | 0.59 |
| ▸ | MC3R | P41968 | 9/20 | 0.58 |
| ▸ | MC1R | Q01726 | 7/20 | 0.58 |
| ▸ | MC5R | P33032 | 9/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888317 | 1.00 | MC4R (0.59) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5888320 | 1.00 | MC4R (0.59) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5888092 | 0.95 | MC4R (0.62) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5888087 | 0.95 | MC4R (0.62) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5888270 | 0.95 | MC4R (0.62) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5887898 | 0.92 | MC4R (0.70) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5887900 | 0.92 | MC4R (0.70) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5888018 | 0.92 | MC4R (0.70) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5888138 | 0.92 | MC4R (0.62) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5888141 | 0.92 | MC4R (0.62) | MC4RMC3RMC1RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026335-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE CO. (US) | 2006-04-11 | — | — | US | claimed |
| US-20050171158-A1 | Melanocortin receptor ligands | EBETINO FRANK H (US) | 2005-08-04 | — | — | US | claimed |
| US-20030236230-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20050026994-A1 | Use of 2, 4diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | FRANCE DENNIS (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171158-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC5R | MC4R 2/4885MC3R 4/4885MC1R 1/4885 |
| US-20050026994-A1 | Use of 2, 4diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | PSMB3, PSMB2, PSMB1 | MC4R 2458/4885MC3R 949/4885MC1R 752/4885 |
| US-20030236230-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC5R | MC4R 2/4885MC3R 4/4885MC1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.